Adam Wieschhaus
Director @ Northpond Ventures
San Francisco, United States
Adam Wieschhaus is a Series A investor at Northpond Ventures in San Francisco focused on Biotechnology and Medical. Adam Wieschhaus is the Director of Northpond Ventures.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 88%
Last updated:
For AI agents: llms.txt
Industries Adam Wieschhaus invests in
Stages Adam Wieschhaus invests in
Countries Adam Wieschhaus invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (75%)
- Medical 2 (25%)
- Health Care 2 (25%)
- Therapeutics 2 (25%)
- Farming 1 (13%)
Stage
- Series A 3 (38%)
- Seed 1 (13%)
- Series B 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. | $26.2M / Series A / Feb 06, 2023 | ||
| Vestaron produces insecticides for agriculture, animal health, non-crop, and commercial pest control applications. Vestaron Corporation develops and produces insecticides by employing peptides sourced from spiders in the United States. Its products are used in agriculture, animal health, and specialty non-crop applications, as well as in-householdinsects and commercial pest control applications. Vestaron Corporation was formerly known as Venomix, Inc. and changed its name to Vestaron Corporation in August 2009. The company was founded in 2005 and is headquartered in Kalamazoo, Michigan. | $10M / Series C / Aug 25, 2022 | ||
| Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing. The company provides non-viral gene delivery systems that facilitate the delivery of mRNA, DNA, and CRISPR Cas9 RNP into cells while retaining cell functionality. Its Flowfect® technology allows high-throughput transfections and scalable optimizationfrom small experiments to large-scale manufacturing.Kytopen’s platforms include Flowfect Discover™ for automated small-volume screening and Flowfect TX® for large-scale delivery, supporting drug discovery and process development. The systems integrate electrical, mechanical, and chemical forces to fine-tune gene delivery, enabling controlled and predictable scaling. The company’s solutions focus on removing bottlenecks in gene delivery and streamlining the transition from laboratory research to therapeutic production. | $30M / Series A / Sep 28, 2021 | ||
| Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. | $23M / Series A / Jul 22, 2021 | ||
| Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts. | $25M / Series A / May 26, 2021 | ||
| Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs. | $7M / Seed / May 05, 2021 | ||
| Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $50M / Series D / Apr 27, 2021 | ||
| Vestaron produces insecticides for agriculture, animal health, non-crop, and commercial pest control applications. Vestaron Corporation develops and produces insecticides by employing peptides sourced from spiders in the United States. Its products are used in agriculture, animal health, and specialty non-crop applications, as well as in-householdinsects and commercial pest control applications. Vestaron Corporation was formerly known as Venomix, Inc. and changed its name to Vestaron Corporation in August 2009. The company was founded in 2005 and is headquartered in Kalamazoo, Michigan. | $18.3M / Series B / Feb 11, 2021 |
Co-Investors
About Northpond Ventures
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Northpond Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Adam Wieschhaus
Director
|
|||
Andrew Lee
Managing Director
|
|||
|
Connor McDermott
Vice President
|
|||
Karthik Bolisetty
Senior Associate
|
|||
Michael Rubin
Founder & CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adam Wieschhaus invest in?
Adam Wieschhaus invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Adam Wieschhaus?
Public channels for Adam Wieschhaus include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Adam Wieschhaus last invest?
The most recent investment recorded for Adam Wieschhaus closed in Feb 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
